Aberrant expression of thyroid transcription factor–1 in schwannomas

Wang, Daizhong; Liu, Ping; Yao, Li; Hao, Yinghua; Zhu, Ruijuan; Zhang, Tao; Tang, Xianbin

doi:10.1016/j.humpath.2017.10.025

Cited by 11 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, TTF-1 immunoreactivity was observed in the MTT component. Given that TTF-1 could be found in 66.7% of schwannomas (2), this result also supported the diagnosis of MTT. Moreover, in the 2017 WHO classification of pituitary tumors (4), TTF-1 expressing pituitary tumors of the posterior lobe represent a morphological spectrum of a single nosological entity.…”

Section: Discussionsupporting

confidence: 71%

“…In the MTT component, immunostaining was positive for Desmin, Myogenin, thyroid transcription factor-1 (TTF-1), and myogenin differentiation 1 (MyoD1). Interestingly, TTF-1, which could be found in 66.7% of schwannomas (2) and is also a novel marker of pituitary tumors of the posterior lobe (3,4), was immunoreactive (Figures 2H). CK was immunonegative in the MTT portion.…”

Section: Case Report History and Presentationmentioning

confidence: 99%

See 1 more Smart Citation

Case report: Concurrent malignant triton tumor and relapsed pituitary adenoma in the sellar region

Wang

Yao²,

Xu³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

Malignant triton tumor (MTT) is a rare kind of malignant peripheral nerve sheath tumors, histologically characterized by rhabdomyoblastic differentiation. There are limited reports of MTT occurring in the intracranial area. The treatment modality consisting of total surgical resection plus post-operative radiotherapy is generally accepted. However, even with optimal treatment, most patients will die within a few months. We report a 71-year-old man with a history of pituitary adenoma, who underwent surgical treatment and postoperative gamma knife therapy. Magnetic resonance imaging (MRI) of the brain revealed a mass with two distinctive components in the sellar area. Postoperative pathology found that the lesion consisted of a MTT and a relapsed pituitary adenoma. The present case is the first report of MTT that occurred in the sellar area. It is also the first case of intracranial MTT with other concurrent tumors (relapsed pituitary tumors). Meanwhile, this case has a clear history of radiation therapy, suggesting that the occurrence of MTT may be related to radiation.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Case Report History and Presentationmentioning

confidence: 99%

Case report: Concurrent malignant triton tumor and relapsed pituitary adenoma in the sellar region

Wang

Yao²,

Xu³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…IHC is now an indispensable tool for diagnostic pathology, but it has many pitfalls, as discussed. As aberrant TTF1 expression in schwannoma was recently reported, 205 we still do not recognize all of them. Therefore, morphologic examination should serve as the foundation of our pathology diagnosis, and all of the aforementioned recommendations are valid only in the proper clinical context.…”

Section: Discussionmentioning

confidence: 78%

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Yatabe

Đačić

Borczuk

et al. 2019

Journal of Thoracic Oncology

256

221

View full text Add to dashboard Cite

Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non-small cell carcinoma, patients' treatment of choice is directly linked to histologic subtypes of non-small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

show abstract

“…SOX-10 is an additional marker of schwannoma that is expressed in the majority of cases [ 1 ]. Interestingly, occasional aberrant expressions of cytokeratins, desmin, and TTF-1 can be found [ 18 , 19 ]. Notably, a mosaic expression pattern of INI1 has been found to be helpful in distinguishing schwannomas, in the context of the different types of schwannomatosis, from apparently sporadically occurring and solitary tumors as [ 20 ].…”

Section: Schwannomamentioning

confidence: 99%

Practical Approach to Histological Diagnosis of Peripheral Nerve Sheath Tumors: An Update

et al. 2022

View full text Add to dashboard Cite

Peripheral nerve sheath tumors encompass a wide spectrum of lesions with different biological behavior, including both benign and malignant neoplasms as well as the recent diagnostic category, i.e., “atypical neurofibromatous neoplasm with uncertain biologic potential” to be used only for NF1 patients. Neurofibromas and schwannomas are benign Schwann-cell-derived peripheral nerve sheath tumors arising as isolated lesions or within the context of classical neurofibromatosis or schwannomatoses. Multiple tumors are a hallmark of neurofibromatosis type 1(NF1) and related forms, NF2-related-schwannomatosis (formerly NF2) or SMARCB1/LZTR1-related schwannomatoses. Perineuriomas are benign, mostly sporadic, peripheral nerve sheath tumors that show morphological, immunohistochemical, and ultrastructural features reminiscent of perineurial differentiation. Hybrid tumors exist, with the most common lesions represented by a variable mixture of neurofibromas, schwannomas, and perineuriomas. Conversely, malignant peripheral nerve sheath tumors are soft tissue sarcomas that may arise from a peripheral nerve or a pre-existing neurofibroma, and in about 50% of cases, these tumors are associated with NF1. The present review emphasizes the main clinicopathologic features of each pathological entity, focusing on the diagnostic clues and unusual morphological variants.

show abstract

Aberrant expression of thyroid transcription factor–1 in schwannomas

Cited by 11 publications

References 40 publications

Case report: Concurrent malignant triton tumor and relapsed pituitary adenoma in the sellar region

Case report: Concurrent malignant triton tumor and relapsed pituitary adenoma in the sellar region

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Practical Approach to Histological Diagnosis of Peripheral Nerve Sheath Tumors: An Update

Contact Info

Product

Resources

About